Jazz Pharmaceuticals (JAZZ) Share-based Compensation Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Jazz Pharmaceuticals | 14.35 Bn | 12.51 Bn | 934.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.66% |
| Dec 31, 2025 | 17.69% |
| Sep 30, 2025 | 23.76% |
| Jun 30, 2025 | 16.06% |
| Mar 31, 2025 | 18.76% |
| Dec 31, 2024 | 22.03% |
| Sep 30, 2024 | 15.73% |
| Jun 30, 2024 | 14.90% |
| Mar 31, 2024 | 17.40% |
| Dec 31, 2023 | 14.65% |
| Sep 30, 2023 | 17.45% |
| Jun 30, 2023 | 18.48% |
| Mar 31, 2023 | 18.32% |
| Dec 31, 2022 | 17.64% |
| Sep 30, 2022 | 15.88% |
| Jun 30, 2022 | 14.52% |
| Mar 31, 2022 | 14.73% |
| Dec 31, 2021 | 16.95% |
| Sep 30, 2021 | 16.44% |
| Jun 30, 2021 | 13.62% |
| Mar 31, 2021 | 7.36% |
| Dec 31, 2020 | 5.23% |
| Sep 30, 2020 | 5.60% |
| Jun 30, 2020 | 5.60% |
| Mar 31, 2020 | 6.60% |
| Dec 31, 2019 | 6.40% |
| Sep 30, 2019 | 9.54% |
| Jun 30, 2019 | 8.80% |
| Mar 31, 2019 | 14.80% |
| Sep 30, 2018 | -4.82% |
| Jun 30, 2018 | 5.36% |
| Mar 31, 2018 | 22.65% |
| Dec 31, 2017 | 28.31% |
| Sep 30, 2017 | 32.62% |
| Jun 30, 2017 | 38.98% |
| Mar 31, 2017 | 50.33% |
| Dec 31, 2016 | 27.17% |
| Sep 30, 2016 | 50.75% |
| Jun 30, 2016 | 49.42% |
| Mar 31, 2016 | 50.35% |
| Dec 31, 2015 | 60.97% |
| Sep 30, 2015 | 60.40% |